focus -WSS

focus

author：hotspot 2025-09-29 00:27:15 - browse：647

There’s a specter haunting Wall Street.

It started in biotech, where companies making drugs for the obesity-related liver disease NASH saw their valuations crash on the assumption that GLP-1 weight loss treatments would cut them out of the market. Then the Ozempic panic came for dialysis firms, whose stocks fell about 20% in a single day on the news that Novo Nordisk’s medicine had delayed the progression of kidney disease in a study enrolling people with type 2 diabetes.

Now analysts from every sector are cranking out research notes on the disparate, dramatic, and often debatable implications of GLP-1 drugs’ growing popularity, said Jared Holz, a health care specialist at Mizuho Securities. Buy Bumble, sell McDonald’s. Short Pepsi, go long Louis Vuitton. Put your money in sectors that cater to a svelte and sated brand of consumer, and get out of the ones that rely on excess and compulsion.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The Supreme Court will review a ruling striking down a domestic violence federal gun ban
Next article： Crinetics acromegaly drug succeeds in late

WSS

AI gets buy

NIH nominee Bertagnolli will get October confirmation hearing

What drug price negotiations mean for Medicare Part D

A protest over insulin prices is seen as a fight for life

AI gets buy

Why Novartis is changing the name of its research labs

knowledge

focus

entertainment

At least 13 dead in Texas as scorching temps continue

Medicaid rebukes states for mistakenly disenrolling children

Psychedelics group wrestles with new pharma identity

Adopting new red light myopia treatments may be short

The cancer drug shortage isn’t new — and neither are the solutions

The (many) problems with a new study criticizing cancer screening

Medicare proposal to cover medical devices draws a mixed reaction

Why CTE doesn’t keep Americans from enjoying the Super Bowl

Hepatitis C has a cure — but many Americans still lack access to it

What drug price negotiations mean for Medicare Part D

hotspot

What drug price negotiations mean for Medicare Part D

A new House health package & hospitals’ new site

A single Democrat is willing to weaken Medicare negotiation power

Why Novartis is changing the name of its research labs

Johnson & Johnson sued for allegedly overpaying for workers' drugs

Covid hospitalizations on the rise, Humana says

Wikipedia

knowledge

hotspot

leisure time